← Back to Search

Amino Acid

L-glutamine for Diverticulosis

Phase 1
Waitlist Available
Research Sponsored by Emmaus Medical, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 48 weeks (12 months)
Awards & highlights

Study Summary

This trial will test whether L-glutamine is a safe and effective treatment for diverticulosis.

Eligible Conditions
  • Diverticulosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 48 weeks (12 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 48 weeks (12 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in the number of colonic diverticula via colonoscopy at 6 and 12 months in patients with diverticulosis.
Secondary outcome measures
Change from baseline the size of colonic diverticula via colonoscopy at 6 and 12 months in patients with diverticulosis
Effect of oral L-glutamine on Hematological Parameters - Hematocrit
Effect of oral L-glutamine on Hematological Parameters - Hemoglobin
+4 more

Side effects data

From 2014 Phase 3 trial • 230 Patients • NCT01179217
81%
Sickle cell anaemia with crisis
25%
Constipation
23%
Nausea
22%
Pyrexia
21%
Headache
18%
Upper respiratory tract infection
17%
Cough
16%
Pain in extremity
15%
Vomiting
14%
Chest pain
13%
Back pain
13%
Arthralgia
12%
Abdominal pain
12%
Acute chest syndrome
11%
Abdominal pain upper
10%
Ocular icterus
9%
Pruritus
8%
Diarrhoea
8%
Acute Chest Syndrome
7%
Urinary tract infection
7%
Nasopharyngitis
7%
Nasal congestion
7%
Oropharnyngeal pain
6%
Pneumonia
6%
Fatigue
6%
Leukocytosis
5%
Anaemia
5%
Oedema peripheral
5%
Dizziness
5%
Tachycardia
5%
Dyspnoea
4%
Hypomanesaemia
4%
Hypokalaemia
3%
Epistaxis
3%
Gastroenteritis
3%
Hyperkalaemia
3%
Asthma
3%
Bronchitis
3%
Hypoxia
2%
Rash
2%
Influenza
1%
Pulmonary embolism
1%
Bronchial hyperreactivity
1%
Cardiac Arrest
1%
Pharnygitis streptococcal
1%
Leucocytosis
1%
Osteomyelitis
1%
Skin ulcer
1%
Sinustitis
1%
Strabismus correction
1%
Dehydration
1%
Gastrointestinal viral infection
1%
Gastritis
1%
Cholelithiasis
1%
Lobar pneumonia
1%
Sepsis
1%
Death
1%
Rhinitis allergic
1%
Joint effusion
1%
Haematuria
1%
Transient ischaemic attack
1%
Post-traumatic reaction
1%
Renal failure acute
1%
Aplastic anaemia
1%
Haemolysis
1%
Hypersplenism
1%
Pain
1%
Cholecystitis
1%
Cholecystitis acute
1%
Complication of device removal
1%
Device malfunction
1%
Fall
1%
Haemolytic transfusion reaction
1%
Pregnancy
1%
Deep vein thrombosis
1%
Thrombophlebits superficial
100%
80%
60%
40%
20%
0%
Study treatment Arm
L-glutamine
100% Maltodextrin

Trial Design

1Treatment groups
Experimental Treatment
Group I: L-glutamineExperimental Treatment1 Intervention
Participants received L-glutamine oral powder 15 grams twice daily for 48 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
L-Glutamine
FDA approved

Find a Location

Who is running the clinical trial?

Emmaus Medical, Inc.Lead Sponsor
7 Previous Clinical Trials
373 Total Patients Enrolled
Yutaka L Niihara, MDStudy ChairEmmaus Medical, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any other experiments that have employed L-glutamine as a tool?

"L-glutamine was first studied in 2011 at the Scarborough District Hospital and since then 35 clinical trials have been finished, with 5 ongoing experiments. Notably, Torrance, California is hosting a major portion of these active tests."

Answered by AI

Has L-glutamine gained regulatory authorization from the FDA?

"There is limited research concerning the safety and efficacy of L-glutamine, so it was given a rating of 1."

Answered by AI

What is the current sample size for this research endeavor?

"Alas, this research endeavour is no longer recruiting new participants. The study began on July 19th 2019 and was last edited November 3rd 2022. If you are still interested in taking part in a clinical trial, there are presently 10 trials examining diverticulosis of the colon and five involving L-glutamine that require volunteers."

Answered by AI

Are there vacancies in this research study for people to join?

"According to the information on clinicaltrials.gov, this trial has stopped recruiting candidates. Initially posted in July of 2019 and last updated in November 2022, it is no longer taking partcipants; however, 15 other trials are currently enrolling patients."

Answered by AI

Who else is applying?

What state do they live in?
Indiana
Texas
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
L-glutamine Treatment in Patients With Diverticulosis
2019. "L-glutamine Treatment in Patients With Diverticulosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05106101.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top